This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-29. Anything still debated is marked as such rather than presented as settled.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.
Several names circulate for the same molecule, including epitalon, epithalone, epithalamin tetrapeptide, and the sequence code AEDG. A CAS registry number, 307297-39-8, is commonly cited for it, though catalogue entries should be checked against supplier documentation because mislabelled records occur. In its usual form the peptide carries free amino and carboxyl termini and is neither glycosylated nor lipidated. Researchers distinguish the defined tetrapeptide from epithalamin itself, a crude pineal preparation containing many peptides that is not chemically characterised.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not an approved drug | Marketed in most countries as a research chemical |
| Main literature language | Russian and English | Early reports concentrated in Russian journals |
| Typical stated purity | ≥95% by HPLC | Supplier declaration, seldom independently verified |
| Principal studied endpoint | Telomerase activity in vitro | Measured in cultured human cells |
| Reported administration routes | Subcutaneous, intranasal | Described in exploratory use reports |
Regulatory status varies by country and is not harmonized. Epitalon is not an approved drug in major Western jurisdictions. In some countries it is sold as a research chemical, and in others it has appeared in products marketed for other categories. This inconsistent status means that purity, labeling accuracy, and documentation differ widely between suppliers, and verification of identity and purity through independent analysis is the usual way buyers assess a given lot.
Epitalon appears in the literature primarily through a small number of research groups, most of them associated with the St. Petersburg Institute of Bioregulation and Gerontology. Publications describe cell culture experiments, animal studies, and a limited number of small human studies. Independent replication outside this network is sparse. As a result, reviews of the topic usually separate descriptive reports of observed effects from the question of whether those effects generalize, and they note the difficulty of comparing studies that use different preparations and endpoints.
Analytical characterization of epitalon relies on standard peptide methods. Reverse-phase high-performance liquid chromatography is used to assess purity, and mass spectrometry confirms identity by checking the observed mass against the expected value near 390 daltons. Amino acid analysis can verify composition. Because the peptide is short and hydrophilic, it elutes early on many reverse-phase columns, so method development often requires ion-pairing reagents to achieve adequate retention and resolution from related impurities.
Interest in epitalon is usually discussed within the broader field of short peptide bioregulators, a category that includes other synthetic di-, tri-, and tetrapeptides studied by the same research group. These compounds share a common rationale: that small fragments of tissue-derived proteins can retain biological activity and can be produced reproducibly. The category as a whole remains outside mainstream pharmacological consensus, and epitalon specifically has a limited presence in independent, non-Russian research literature, which shapes how its evidence base is described.
Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.
The four residues give epitalon a molecular formula of C14H22N4O9 and a molecular weight near 390.35 daltons. The presence of two acidic residues, glutamate and aspartate, makes the free peptide strongly acidic, while the alanine and glycine ends provide neutral, nonpolar character. This combination produces a molecule with substantial water solubility. Because there are no cysteine, methionine, or tryptophan residues, the peptide lacks the most common oxidation-sensitive side chains, which simplifies handling compared with many longer peptides.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
sulfur amino acid metabolic processes DNA methylation methionine metabolic processes methionine biosynthetic processes methylation S-adenosylmethionine (SAM) cycle homocysteine catabolic processes folic acid metabolic processes oxidation-reduction processes negative regulation of cystathionine beta-synthase activity.
The prevalent in political circles nationalism was fueled by the large size of Poland's minority populations and their separate agendas. According to the language criterion of the Polish census of 1931, the Poles constituted 69% of the population, Ukrainians 15%, Jews (defined as speakers of the Yiddish language) 8.5%, Belarusians 4.7%, Germans 2.2%, Lithuanians 0.25%, Russians 0.25% and Czechs 0.09%, with some geographical areas dominated by a particular minority. In time, the ethnic conflicts intensified, and the Polish state grew less tolerant of the interests of its national minorities. In interwar Poland, compulsory free general education substantially reduced illiteracy rates, but discrimination was practiced in a way that resulted in a dramatic decrease in the number of Ukrainian language schools and official restrictions on Jewish attendance at selected schools in the late 1930s. The population grew steadily, reaching 35 million in 1939. However, the overall economic situation in the interwar period was one of stagnation. There was little money for investment inside Poland, and few foreigners were interested in investing there. Total industrial production barely increased between 1913 and 1939 (within the area delimited by the 1939 borders), but because of population growth (from 26.3 million in 1919 to 34.8 million in 1939), the per capita output actually decreased by 18%.
[N]o peer competitor has yet emerged more than a decade after the end of US-Soviet bipolarity to balance against the United States. Contrary to realist predictions, unipolarity has not provided the global alarm to restore a balance of power.
Sources: en.wikipedia.org
In dermatology, the base of a topical medication is often as important as the medication itself. It is extremely important to receive a medication in the correct base, before applying to the skin. A pharmacist should not substitute an ointment for a cream, or vice versa, as the potency of the medication can change. Some physicians use a thick ointment to replace the waterproof barrier of the inflamed skin in the treatment of eczema, and a cream might not accomplish the same clinical intention.
=== Scientific journal articles === Holick, MF (2007). "Vitamin D deficiency". N Engl J Med. 357 (3): 266–81. doi:10.1056/NEJMra070553. PMID 17634462. S2CID 18566028. Holick, MF (2006). "Resurrection of vitamin D deficiency and rickets". J Clin Invest. 116 (8): 2062–72. doi:10.1172/JCI29449. PMC 1523417. PMID 16886050. Pietras, SM; Obayan, BK; Chai, MH; Holick, MF (2010). "Vitamin D2 treatment for vitamin D deficiency and insufficiency for up to 6 years". Arch Intern Med. 169 (19): 1806–8. doi:10.1001/archinternmed.2009.361. PMID 19858440. Biancuzzo, RM; Young, A; Bibuld, D; Cai, MH; Winter, RM; Klein, EK; Ameri, A; Reitz, R; Salameh, W; Chen, TC; Holick, MF (2010). "Fortification of orange juice with vitamin D(2) or vitamin D(3) is as effective as an oral supplement in maintaining vitamin D status in adults". Am J Clin Nutr. 91 (6): 1621–6. doi:10.3945/ajcn.2009.27972. PMC 2869510. PMID 20427729. Holick, MF; Binkley, NC; Bischoff-Ferrari, HA; Gordon, CM; Hanley, DA; Heaney, RP; Murad, MH; Weaver, CM; et al. (2011). "Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline". J Clin Endocrinol Metab. 96 (7): 1911–30. doi:10.1210/jc.2011-0385. PMID 21646368.
== Erinacine A == Erinacine A, isolated from the cultured mycelia of Hericium erinaceus, the main representative of this compounds group, has an enhancing effect on nerve growth factor synthesis in vitro. It also increases the levels of catecholamines in the central nervous system of rats.. Erinacine A has been observed to lead to the activation of antioxidant pathways including the transcription factor Nrf2. Stimulator of nerve growth factor (NGF) synthesis in vitro((250.1 ± 36.2) pg/mL at 1.0 mmol/L), weak cytotoxicity against PC12 cells (IC50: 73.7 μmol/L), Anti‐methicillin-resistant Staphylococcus aureus (MRSA) activity Erinacine A has also been prepared by total synthesis.
== Integration with precision medicine == Integrating improved pharmacometrics, along with model-informed precision dosing (MIPD), can further refine therapeutic drug monitoring to provide more precisely personalized treatments. Data from these approaches can be integrated into the electronic patient record in the form of clinical decision support systems (CDSSs), providing improved information to clinicians and caregivers.
Sources: en.wikipedia.org
=== Extra-articular complications === Extra-articular complications (in which inflammation affects other organs or areas of the body other than the joints) is very common in JIA. Chronic anterior uveitis (inflammation of the anterior portion of the eye) is seen in 20-30% of children with oligoarticular JIA. RF-negative polyarticular JIA and psoriatic JIA also often have chronic anterior uveitis. Girls younger than 6-years old with positive ANA (Anti-nuclear antibodies) are at the highest risk, and 90% of cases occur within 4 years of JIA onset. Acute anterior uveitis occurs in 11-13% of patients with JIA, most commonly in the enthesitis related variant of JIA. It is associated with light sensitivity, conjunctivitis and eye pain. Treatment consists of steroid eye drops and systemic DMARDs. Both acute and chronic anterior uveitis require regular eye exams to monitor for complications. Macrophage activation syndrome is an acute hyperinflammatory complication of JIA that is life treatening. It is a type of acquired hemophagocytic lymphohistiocytosis that is triggered by hyperinflammation of rheumatologic diseases such as JIA. It occurs in 10% of JIA patients. It is treated by interferon-γ inhibitors, interleukin-1 (IL-1) inhibitors and systemic steroids.
Glucose is converted into glucose 6-phosphate by the action of glucokinase or hexokinase with conversion of ATP to ADP. Glucose-6-phosphate is converted into glucose-1-phosphate by the action of phosphoglucomutase, passing through the obligatory intermediate glucose-1,6-bisphosphate. Glucose-1-phosphate is converted into UDP-glucose by the action of the enzyme UDP-glucose pyrophosphorylase. Pyrophosphate is formed, which is later hydrolysed by pyrophosphatase into two phosphate molecules. The enzyme glycogenin is needed to create initial short glycogen chains, which are then lengthened and branched by the other enzymes of glycogenesis. Glycogenin, a homodimer, has a tyrosine residue on each subunit that serves as the anchor for the reducing end of glycogen. Initially, about seven UDP-glucose molecules are added to each tyrosine residue by glycogenin, forming α(1→4) bonds. Once a chain of seven glucose monomers is formed, glycogen synthase binds to the growing glycogen chain and adds UDP-glucose to the 4-hydroxyl group of the glucosyl residue on the non-reducing end of the glycogen chain, forming more α(1→4) bonds in the process. Branches are made by glycogen branching enzyme (also known as amylo-α(1:4)→α(1:6)transglycosylase), which transfers the end of the chain onto an earlier part via α-1:6 glycosidic bond, forming branches, which further grow by addition of more α-1:4 glycosidic units.
== Occurrence == Dimethyl trisulfide has been found in volatiles emitted from cooked onion, leek and other Allium species, from broccoli and cabbage, as well as from Limburger cheese, and is involved in the unpalatable aroma of aged beer and stale Japanese sake. It is a product of bacterial decomposition, including the early stages of human decomposition, and is a major attractant for blowflies looking for hosts. Dimethyl trisulfide along with dimethyl sulfide and dimethyl disulfide have been confirmed as volatile compounds given off by the fly-attracting plant known as dead-horse arum (Helicodiceros muscivorus). These flies are attracted to the odor of fetid meat and help pollinate this plant. DMTS contributes to the foul odor given off by the fungus Phallus impudicus, also known as the common stinkhorn. DMTS causes the characteristic malodorous smell of a fungating lesion, e.g., from cancer wounds, and contributes to the odor of human feces. DMTS can be synthesized by the reaction of methanethiol with hydrogen sulfide (in the presence of copper (II)) and with sulfur dichloride, among other methods:
Sources: en.wikipedia.org
Small studies with human participants have been reported, chiefly in Russian-language journals, but they are limited in size and design. No large randomised controlled trial with published results is available.
The most reproducible biochemical observation comes from cultured cells, where the peptide was reported to raise telomerase activity. Whether this translates into measurable health effects in animals or humans is not established.
It is offered as a research chemical for laboratory use, which places it outside the approval pathways applied to medicines. Buyers should expect documentation to differ between suppliers.
It is a synthetic tetrapeptide. Its sequence was derived from research on peptide fractions of bovine pineal extract, and the intact AEDG sequence has not been demonstrated as an abundant free peptide in human tissue.